SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-116712
Filing Date
2023-11-13
Accepted
2023-11-13 07:46:23
Documents
14
Period of Report
2023-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2330394d1_8k.htm   iXBRL 8-K 26493
2 EXHIBIT 99.1 tm2330394d1_ex99-1.htm EX-99.1 132568
3 GRAPHIC tm2330394d1_ex99-1img001.gif GRAPHIC 4909
  Complete submission text file 0001104659-23-116712.txt   356179

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vyne-20231113.xsd EX-101.SCH 3042
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vyne-20231113_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vyne-20231113_pre.xml EX-101.PRE 22377
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2330394d1_8k_htm.xml XML 3412
Mailing Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 231395161
SIC: 2834 Pharmaceutical Preparations